Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021

A COVID-19 primer for primary care clinicians

“… 69 A more recent meta-analysis published in September 2021 estimated the pooled effectiveness of the Pfizer-BioNTech vaccine to be 92.4% in preventing symptomatic laboratory-confirmed COVID-19, 94.3% effective in preventing COVID-19-related hospitalizations, 96.1% protective against COVID-19-related deaths, and 89.3% effective in preventing asymptomatic SARS-CoV-2 infection. 70 However, one should note that most of the data collection and analysis occurred prior to widespread circulation of the Delta and Omicron variants.…”

The COVID-19 pandemic in children and young people during 2020-2021: A complex discussion on vaccination

“…The additional information increased certainty that benefits from prevention of asymptomatic infection, COVID-19, and associated hospitalization and death outweighs vaccine-associated risks. On August 30, 2021, ACIP issued a recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19 [ 157 ].…”

Recombinant VLPs empower RBM peptides showing no immunogenicity in native SARS-COV-2 protein to elicit a robust neutralizing antibody response

“…The vaccine is believed to be the most valuable approach to stop the spread of COVID-19 pandemic. At present, several forms of vaccine based on various platforms have been validated by the World Health Organization (WHO) for emergency use, including nanoparticle mRNA vaccine ( 2 ), adenovirus vector vaccine ( 3 ), and inactivated virus vaccine ( 4 ); In addition，China have also approved a recombinant subunit vaccine ( 5 ). It was reported that CoronaVac，an inactivated virus vaccine，produced a primary efficacy against symptomatic COVID-19 about 50.7%, and a secondary efficacy against cases requiring assistance and moderate or severe cases about 83.7% and 100% respectively ( 6 ).…”